Xevinapant
As of the edition of 20 October 2026, Xevinapant is a small molecule: stopped in 2025; acts on BIRC2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 18, 10 stopped early
- Disease areas
- Cancer; Lungs and airways; Ear, nose and throat; Blood and lymph; Digestive system; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Xevinapant.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BIRC2 | Baculoviral IAP repeat-containing protein 2 | Q13490 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 10 | 5 | 0 | 5 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Debiopharm | Lead sponsor of trials | 2010 to now |
| Ascenta Therapeutics | Lead sponsor of trials | 2011 to now |
| Merck KGaA | Lead sponsor of trials | 2020 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2022 to now |